Everest Medicines (HKEX:1952.HK) has announced that its licensing partner, Venatorx Pharmaceuticals, reported positive results from a Phase 3 study investigating the use of cefepime-taniborbactam in hospitalized adults with complicated urinary tract infections (cUTI), including acute pyelonephritis.
The study pitted cefepime-taniborbactam against meropenem. First approved in 1996, meropenem is used to treat various bacterial infections.
In the Phase 3 CERTAIN-1 (Cefepime Rescue with Taniborbactam in cUTI) study, cefepime-taniborbactam met the primary efficacy endpoint of statistical non-inferiority (NI) to meropenem.
Cefepime is a commonly used beta-lactam (BL) antibiotic, while taniborbactam is a novel beta-lactamase inhibitor.
A total of 661 patients participated in the trial who were randomized 2:1 to receive cefepime-taniborbactam 2.5 g q8h or meropenem 1g q8h for seven days. Patients with bacteremia were treated for up to 14 days.